Recursion Pharmaceuticals (RXRX) Total Non-Current Liabilities (2023 - 2026)

Recursion Pharmaceuticals' Total Non-Current Liabilities history runs 4 years deep, the most recent figure standing at $312.7 million for Q1 2026.

• Quarterly Total Non-Current Liabilities fell 14.67% year-over-year to $312.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $312.7 million (down 14.67% YoY) and the FY2025 annual result came in at $341.2 million, down 16.6% from the prior year.
• Total Non-Current Liabilities was $312.7 million for Q1 2026 at Recursion Pharmaceuticals, down from $341.2 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $409.1 million in Q4 2024 and bottomed at $188.4 million in Q2 2024.
• A 4-year average of $304.5 million and a median of $341.2 million in 2025 frame the typical range for Total Non-Current Liabilities.
• Annual changes were most pronounced in 2024 — Total Non-Current Liabilities surged 115.01% — and 2025, when it dropped 16.6%.
• Recursion Pharmaceuticals' Total Non-Current Liabilities stood at $190.3 million in 2023, then jumped by 115.01% to $409.1 million in 2024, then fell by 16.6% to $341.2 million in 2025, then decreased by 8.34% to $312.7 million in 2026.
• Business Quant data shows RXRX's Total Non-Current Liabilities at $312.7 million in Q1 2026, $341.2 million in Q4 2025, and $351.5 million in Q3 2025.